Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Captrust Financial Advisors

Captrust Financial Advisors lessened its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 16.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,048 shares of the pharmaceutical company's stock after selling 2,361 shares during the period. Captrust Financial Advisors' holdings in Vertex Pharmaceuticals were worth $4,852,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in VRTX. Brown Lisle Cummings Inc. acquired a new stake in Vertex Pharmaceuticals in the fourth quarter valued at approximately $30,000. Sugar Maple Asset Management LLC acquired a new stake in Vertex Pharmaceuticals in the 4th quarter valued at $35,000. Golden State Wealth Management LLC purchased a new stake in Vertex Pharmaceuticals in the 4th quarter worth $37,000. Truvestments Capital LLC raised its position in Vertex Pharmaceuticals by 30.3% during the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock worth $40,000 after acquiring an additional 23 shares during the period. Finally, ORG Partners LLC lifted its holdings in Vertex Pharmaceuticals by 108.2% during the fourth quarter. ORG Partners LLC now owns 102 shares of the pharmaceutical company's stock valued at $41,000 after purchasing an additional 53 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company's stock.

Insider Activity

In other news, EVP David Altshuler sold 3,231 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the sale, the executive vice president now owns 26,512 shares of the company's stock, valued at approximately $13,256,000. This trade represents a 10.86 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Ourania Tatsis sold 244 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total value of $111,034.64. Following the completion of the transaction, the executive vice president now directly owns 67,695 shares of the company's stock, valued at $30,805,286.70. This trade represents a 0.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 4,315 shares of company stock worth $2,121,012. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Trading Down 1.0 %

NASDAQ:VRTX opened at $425.30 on Friday. The stock has a fifty day moving average price of $488.74 and a 200 day moving average price of $465.90. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The firm has a market cap of $109.34 billion, a PE ratio of -193.32, a price-to-earnings-growth ratio of 2.11 and a beta of 0.51.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). The company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.85 billion. Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. The business's quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.76 earnings per share. Sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. BMO Capital Markets set a $545.00 price target on shares of Vertex Pharmaceuticals in a research note on Friday, January 31st. Royal Bank of Canada increased their price objective on Vertex Pharmaceuticals from $420.00 to $423.00 and gave the company a "sector perform" rating in a research note on Tuesday. Truist Financial lifted their target price on shares of Vertex Pharmaceuticals from $460.00 to $520.00 and gave the stock a "buy" rating in a research note on Tuesday, February 11th. StockNews.com raised shares of Vertex Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Tuesday, March 11th. Finally, The Goldman Sachs Group reaffirmed a "buy" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday. Thirteen equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $515.04.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.